New Real-Time Reverse Transcriptase-Initiated PCR Assay with Single-Copy Sensitivity for Human Immunodeficiency Virus Type 1 RNA in Plasma

By S. Palmer, A. Wiegand, F. Maldarelli, Holly Z. Bazmi, J. Mican, M. Polis, R. Dewar, Angeline Planta, Shuying Liu, J. Metcalf and 2 more. Journal of Clinical Microbiology, 2003

621 citations recorded by the source corpus.

Subfields: Infectious Diseases, Virology

View Paper: https://www.semanticscholar.org/paper/98fc37eaec5841fe6a4a0a3366e10fd868632a80

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

M. Perreau
S. Migueles
S. Palmer
N. Archin
C. M. Osborne
F. Maldarelli
A. Savoye
C. Royce

Citations in the corpus

Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production (2013, methodology): “Residual HIV replication is supported by studies showing that low level plasma viremia, i.e., <20 HIV RNA copies/ml, can be measured using more sensitive assays in a large number of subjects (Dornadula et al., 1999; Palmer et al., 2003).”
Lytic Granule Loading of CD8+ T Cells Is Required for HIV-Infected Cell Elimination Associated with Immune Control (2008, positive): “We examined the relationship between viral replication and CD8+ T cell frequency in these patient populations (Tables S1 and S2 available online) by using a newer assay with a lower detection limit of 1 copy/ml (Palmer et al., 2003).”
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy (2012, methodology): “Additionally, we measured singlecopy assay viremia [17] on four occasions prior to VOR exposure, and at 8 and 24 hours after doses of 200, 400, and 400 mg of VOR (10 assays in total).”
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy (2008, methodology): “Using a recently developed real-time HIV RNA assay with single-copy sensitivity (10), our prior work has shown that 80% of patients on suppressive standard protease inhibitor or nonnucleoside reverse transcriptase inhibitor-containing antiretroviral therapy for 60 weeks had measurable levels of pers”